Folkehelseinstituttet [the Norwegian Institute of Public Health] is holding an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups for the seasons 2022/2023.

Folkehelseinstituttet [the Norwegian Institute of Public Health] is holding an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition is lowest price. The tender documentation has several minimum requirements for the vaccine. All the minimum requirements must be fulfilled.

The procurement will be carried out in accordance with the Public Procurement Act of 17 June 2016 (PPA) and the Public Procurement Regulations (PPR) part I and part III. A contract will be awarded in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

FHI has received signal that there will be significant risk that doses cannot be allocated to Norway if the procurement process is not carried out before the middle of December. As FHI cannot risk Norway being left without doses, it has been decided to hold a contest with a 15 day tender deadline. Incidentally, the procurement will be carried out in-line with the procurement regulations.

The total contract volume is 700,000 - 900,000 doses

In this contest, the Norwegian Institute of Public Health in consideration of preparedness, will primarily aims to award two sub-contracts where the total volume is distributed as follows:

60% of total volume, 420,000 - 540,000 doses

40% of total volume, 280,000 - 360,000 doses

The actual number of doses will be clear upon award.

See Chapter 6 of the tender documentation ‘Award Criteria’ with sub-points for further description.

Also see the tender documentation point 1.9 ‘Special contract terms’

First delivery in the new contract is anticipated to be before 20 September 2022.

Contract terms are given in Annex 1, ‘Supply Agreement’.

Folkehelseinstituttet [the Norwegian Institute of Public Health] is holding an open tender contest with the aim of ensuring sufficient delivery of four valent vaccine against seasonal influenza (ATC code J07B B02) for vaccination of adults in defined risk groups (see point 1.4) for the seasons 2022/2023.

The Norwegian Institute of Public Health already has the existing contracts for four valent seasonal influenza vaccine for the season 2022/2023 with respectively Sanofi Aventis (Vaxigriptetra) and Mylan Healthcare (Influvac Tetra), with a combined volume of 900,000 doses. Increased national request for seasonal influenza vaccine in recent years makes it necessary to carry out supplementary procurement for the season 2022/2023, in order to cover the need beyond the volume in the existing contracts.

The only award criteria in the competition is lowest price. The tender documentation has several minimum requirements for the vaccine. All the minimum requirements must be fulfilled.

The procurement will be carried out in accordance with the Public Procurement Act of 17 June 2016 (PPA) and the Public Procurement Regulations (PPR) part I and part III. A contract will be awarded in accordance with the open tender contest procedure, cf. the Public Procurement Regulations § 13-1 (1).

FHI has received signal that there will be significant risk that doses cannot be allocated to Norway if the procurement process is not carried out before the middle of December. As FHI cannot risk Norway being left without doses, it has been decided to hold a contest with a 15 day tender deadline. Incidentally, the procurement will be carried out in-line with the procurement regulations.

The total contract volume is 700,000 - 900,000 doses

In this contest, the Norwegian Institute of Public Health in consideration of preparedness, will primarily aims to award two sub-contracts where the total volume is distributed as follows:

60% of total volume, 420,000 - 540,000 doses

40% of total volume, 280,000 - 360,000 doses

The actual number of doses will be clear upon award.

See Chapter 6 of the tender documentation ‘Award Criteria’ with sub-points for further description.

Also see the tender documentation point 1.9 ‘Special contract terms’

First delivery in the new contract is anticipated to be before 20 September 2022.

Contract terms are given in Annex 1, ‘Supply Agreement’.